NATERA INC (Common Stock) – ticker 45E (NTRA)
Natera & Angiex Partner to Evaluate AGX101 Response With Signatera
NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.
Natera Supports Kupando Trial to Advance ctDNA Monitoring in Cancer
NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.
Natera Spotlights Record Signatera Volumes, Raises Outlook at Canaccord Conference
Natera NASDAQ: NTRA Chief Financial Officer Mike Brophy said the company delivered strong second-quarter momentum across its women's health, oncology and organ health businesses, citing record Signatera volumes, continued revenue and average selling price strength, improved gross margins and narrowing losses while maintaining elevated investment levels.
Natera Q2 Earnings Call Highlights
Natera NASDAQ: NTRA reported second-quarter 2026 revenue of approximately $753 million, up about 38% from a year earlier, as record testing volumes and higher average selling prices supported growth across its oncology, women's health and organ health businesses.
Natera (NTRA) Reports Q2 Loss, Beats Revenue Estimates
Natera (NTRA) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.74 per share a year ago.
Natera, Inc. (NTRA) Q2 2026 Earnings Call Transcript
Natera, Inc. (NTRA) Q2 2026 Earnings Call Transcript
NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers
Natera's Signatera became the first personalized MRD test for solid tumors to earn EU IVDR certification, supporting broader expansion across Europe.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck Cancer
Natera's Aveta partnership brings Signatera into a global Phase 3 head and neck cancer trial to assess MRD and treatment response.
NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan
Natera's Signatera gains Japan PMDA approval for CRC, marking the country's first approved MRD test and advancing its global expansion.
Natera (NTRA) Stock Jumps 10.7%: Will It Continue to Soar?
Natera (NTRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
